Gastrointestinal angiodysplasia is associated with significant gastrointestinal bleeding in patients with continuous left ventricular assist devices

 

 Permissions and Reprints

Background and study aims: Patients with a continuous-flow left ventricular assist device (LVAD) have a 65 % incidence of bleeding events within the first year. The majority of gastrointestinal bleeding (GIB) is from gastrointestinal angiodyplasia (GIAD). The primary aim of the study was to determine whether GIAD was associated with a higher rate of significant bleeding, an increased number of bleeding events per year, and a higher rate of transfusion compared to non-GIAD sources.

Patients and methods: This retrospective cohort study included 118 individuals who received a LVAD at a tertiary medical center from 2006 through 2014. Patients were subdivided into GIB and non-GIB for comparison of patient demographics, comorbid conditions, and laboratory data. GIB was further divided into sources of GIB, GIAD, obscure, or non-GIAD to establish severity of bleeding, rate of re-bleeding, and transfusion rate.

Results: GIAD is associated with an increased number of bleeding events compared to non-GIAD sources of GIB (2.07 vs 1.23, P = 0.01) and a higher number of bleeding events per year (0.806 vs. 0.455 P = 0.001). GIAD compared to non-GIAD sources of GIB was associated with an increased incidence of major bleeding (100 % vs 60 %, P = 0.006) and increased rates of transfusion (8.8 vs 2.95 units, P = 0.0004). Cox Regression analysis between non-GIB and GIAD demonstrated increased risk with age (P = 0.001), history of chronic kidney disease (P = 0.005), and length of stay after LVAD implantation of more than 45 days (P = 0.04). History of hypertension (P = 0.045), diabetes mellitus (P = 0.016), and male gender was associated with decreased risk (P = 0.04).

Conclusion: Patients with a continuous-flow LVAD who develop a GIB secondary to GIAD have a higher rate of major bleeding, multiple bleeding events, and require more transfusions to achieve stabilization compared to patients who do not have GIAD.

• References

• 1 Miller LW, Pagnani ED, Russell SD et al. Use of continuous-flow devices in patients awaiting heart transplant. NEJM 2007; 357: 885-896
  CrossrefPubMedGoogle Scholar
• 2 Crow S, Chen D, Milano C et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 2010; 90: 1263-1269
  CrossrefPubMedGoogle Scholar
• 3 John R, Kamdar F, Liao K et al. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg 2008; 86: 1227-1234
  CrossrefPubMedGoogle Scholar
• 4 Kirklin JK, Naftel DC, Kormos RL et al. Second INTERMACS annual report: more than 1000 primary left ventricular assist device implants. J Heart Lung Transplant 2010; 29: 1-10
  CrossrefPubMedGoogle Scholar
• 5 Crow S, John R, Boyle A et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009; 137: 208-215
  CrossrefPubMedGoogle Scholar
• 6 Aggarwal A, Pant R, Kumar S et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg 2012; 93: 1534-1540
  CrossrefPubMedGoogle Scholar
• 7 Uriel N, Pak SW, Jorde UP et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010; 56: 1207-1213
  CrossrefPubMedGoogle Scholar
• 8 Wever-Pinzon O, Selzman CH, Drakos SG et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013; 6: 517-526
  CrossrefPubMedGoogle Scholar
• 9 Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Eng J Med 1958; 259: 196
  PubMedGoogle Scholar
• 10 Demirozu ZT, Radovanceivic R, Hochman LF et al. Arteriovenous malformation and gastrointestinal bleeding in patients with Heartmate II left ventricular device. J Heart Lung Transplant 2011; 30: 849-853
  PubMedGoogle Scholar
• 11 Pennington DG, Mcbride LR, Peigh PS et al. Eight years experience with bridging to cardiac transplantation. J Thoracic Cardiovasc Surg 1994; 107: 472-481
  PubMedGoogle Scholar
• 12 Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc 2014; 80: 435-446
  CrossrefPubMedGoogle Scholar
• 13 Kushnir VM, Sharma S, Ewald GA et al. Evaluation of GI bleeding after implantation of left ventricular assist device. Gastrointest Endosc 2012; 75: 973-979
  CrossrefPubMedGoogle Scholar
• 14 Singh G, Albeldawi M, Kalra S et al. Features of Patients with Gastrointestinal Bleeding After Implantation of an Assist Device. Clin Gastr Hepat 2015; 13: 107-114
  PubMedGoogle Scholar
• 15 Tsiouris A, Paone G, Nemeh HW et al. Factors determining post-operative readmissions after left ventricular assist device implantation. Heart Lung Transplant 2014; 33: 1041-1047
  CrossrefPubMedGoogle Scholar
• 16 Forest SJ, Bello R, Friedmann P et al. Readmissions after ventricular assist device: etiologies, patterns, and days out of hospital. Ann Thorac Surg 2013; 95: 1276-1281
  CrossrefPubMedGoogle Scholar
• 17 Sarosiek K, Bogar L, Conn MI et al. An old problem with a new therapy: gastrointestinal bleeding in ventricular assist device patients and deep overtube-assisted enteroscopy. ASAIO J 2013; 59: 384-389
  CrossrefPubMedGoogle Scholar
• 18 Jackson CS, Gerson LB. Management of Gastrointestinal Angiodysplastic Lesions (GIADs): A Systematic Review and Meta-Analysis. Am J Gastroenterol 2014; 109: 474-483
  CrossrefPubMedGoogle Scholar
• 19 Uriel N, Pak SW, Jorde UP et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010; 56: 1207-1213
  CrossrefPubMedGoogle Scholar
• 20 Randi AM, Laffan MA, Starke RD. Von Willebrand factor, angiodysplasia and angiogenesis. Mediterr J Hematol Infect Dis 2013; 5 (1)
  PubMedGoogle Scholar
• 21 Daly C, Eicthen A, Castanaro C et al. Angiopoeitin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013; 73: 108-118
  PubMedGoogle Scholar
• 22 Starke RD, Ferraro F, Paschalaki KE et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117: 1071-1080
  CrossrefPubMedGoogle Scholar
• 23 Veyradier A, Balian A, Wolf M et al. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001; 120: 346-353
  CrossrefPubMedGoogle Scholar
• 24 Hoog CM, Brostrom O, Lindahl TL et al. Bleeding from gastrointestinal angioectasias is not related to bleeding disorders- a case control study. BMC Gastroenterol 2010; 10: 113
  CrossrefPubMedGoogle Scholar
• 25 Junquera F, Saperas E, de Torres I et al. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94: 1070-1076
  CrossrefPubMedGoogle Scholar
• 26 Ge ZZ, Chen HM, Gao YJ et al. Efficacy of thalidomide for refractors gastrointestinal bleeding from vascular malformation. Gastroenterology 2011; 14: 1629-1637
  PubMedGoogle Scholar
• 27 Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: Bench to bedside. Gastroenterology 2008; 135: 41-60
  CrossrefPubMedGoogle Scholar